These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28835285)

  • 41. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis.
    Schuller Y; Gispen-de Wied C; Hollak CEM; Leufkens HGM; Stoyanova-Beninska V
    J Clin Pharmacol; 2019 Feb; 59(2):229-244. PubMed ID: 30192386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
    Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
    Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Research advances in pharmacotherapy for rare diseases in children].
    Li JQ; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jul; 25(7):759-766. PubMed ID: 37529960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations for the design of small population clinical trials.
    Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
    Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.
    Schuller Y; Hollak CEM; Gispen-de Wied CC; Stoyanova-Beninska V; Biegstraaten M
    Drugs; 2017 Sep; 77(13):1461-1472. PubMed ID: 28752290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T; Lampert A; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trends of Clinical Trials for Drug Development in Rare Diseases.
    Sakate R; Fukagawa A; Takagaki Y; Okura H; Matsuyama A
    Curr Clin Pharmacol; 2018; 13(3):199-208. PubMed ID: 29866013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Orphan drug development: the increasing role of clinical pharmacology.
    Ahmed MA; Okour M; Brundage R; Kartha RV
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):395-409. PubMed ID: 31338634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges.
    Wu X; Xu W; Yu M; Zhang F; Wang H
    Pharmacol Res; 2022 Aug; 182():106349. PubMed ID: 35835367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orphan drug designation and development in Japan: 25 years of experience and assessment.
    Sakushima K; Takeda H; Aoi Y
    Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
    [No Abstract]   [Full Text] [Related]  

  • 59. A new toolkit for conducting clinical trials in rare disorders.
    Abrahamyan L; Diamond IR; Johnson SR; Feldman BM
    J Popul Ther Clin Pharmacol; 2014; 21(1):e66-78. PubMed ID: 24671886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.